- 1 Title:
- 2

3 Duration of viral shedding and culture positivity with post-vaccination breakthrough delta

- 4 variant infections
- 5
- 6 Authors:
- 7 Mark J. Siedner^{1,2}
- 8 Julie Boucau³
- 9 Rebecca Gilbert¹
- 10 Rockib Uddin¹
- 11 Jonathan Luu⁴
- 12 Sebastien Haneuse⁴
- **13** Tammy Vyas¹
- 14 Zahra Reynolds¹
- 15 Surabhi Iyer¹
- 16 Grace Chamberlin¹
- 17 Robert H. Goldstein^{1,2}
- 18 Crystal M. North^{1,2}
- 19 Chana A. Sacks^{1,2}
- 20 James Regan⁵
- 21 James P. Flynn⁵
- 22 Manish C. Choudhary^{2,5}
- 23 Jatin M. Vyas^{1,2}
- 24 Amy Barczak*^{1, 2, 3}
- 25 Jacob Lemieux^{*1,2,6}
- 26 Jonathan Z. Li^{*2,5}
- 27

29

- 28 *These authors contributed equally to this manuscript
- 30 Affiliations:
- 1. Massachusetts General Hospital, Boston, MA, USA
- 32 2. Harvard Medical School, Boston, MA, USA
- 33 3. Ragon Institute of MGH, MIT and Harvard
- 34 4. TH Chan Harvard School of Public Health
- 5. Brigham and Women's Hospital, Boston, MA, USA
- **36 6**. Broad Institute
- 37
- 38 Conflicts of Interest: None
- 39
- 40 Funding:
- 41 This work was supported in part by the Massachusetts Consortium on Pathogen Readiness
- 42 and the Harvard Center for AIDS Research, a National Institutes of Health funded
- 43 program [P30AI060354].
- 44

45 Abstract

46	Isolation guidelines for SARS-CoV-2 are largely derived from data collected prior to emergence of
47	the delta variant. We followed a cohort of ambulatory patients with post-vaccination breakthrough
48	SARS-CoV-2 infections with longitudinal collection of nasal swabs for SARS-CoV-2 viral load
49	quantification, whole genome sequencing, and viral culture. All delta variant infections (8/8, 100%)
50	in our cohort were symptomatic, compared with $64\% (9/14)$ of non-delta variant infections. Delta
51	variant breakthrough infections were characterized by higher initial viral load, longer duration of
52	virologic shedding by PCR (median 13.5 vs 4 days, hazard ratio [HR] 0.45, 95%CI 0.17-1.17),
53	greater likelihood of replication-competent virus at early stages of infection $(6/8 [75\%] \text{ vs } 3/14$
54	[23%], P=0.03), and longer duration of culturable virus (median 7 vs 3 days, HR 0.38, 95%CI
55	0.14-1.02) compared to non-delta variants. Nonetheless, no individuals with delta variant infections
56	had replication-competent virus by day 10 after symptom onset or 24 hours after resolution of
57	symptoms. These data support current US Center for Disease Control isolation guidelines and
58	reinforce the importance of prompt testing and isolation among symptomatic individuals with delta
59	variant breakthrough infections. Additional data are needed to evaluate these relationships among
60	asymptomatic and more severe delta variant breakthrough infections.
61	

62 Background

63	Isolation and distancing practices are fundamental elements of COVID-19 epidemic control.
64	Current guidelines authored by the US Centers for Disease Control and Prevention (CDC)
65	recommend most individuals infected with SARS-CoV-2 virus remain isolated for 10 days after a
66	positive test (if asymptomatic) or 10 days from onset of symptoms and 1 day after resolution of
67	symptoms (for symptomatic infections) (1). These guidelines were largely developed based on the
68	low likelihood of recovering replication-competent virus after 10 days of symptoms for most
69	patients (2–5), prior to the emergence of the delta variant as the dominant circulating strain
70	globally (6). The delta variant has been associated with a higher basic reproductive number (7),
71	higher viral loads at detection of infection (8), higher replication efficiency (9), and shorter
72	incubation period and generation time (10). However, there are few longitudinal data on delta
73	variant infections that describe the duration of contagiousness or isolation of replication-competent
74	virus, particularly with post-vaccination breakthrough infections.

75

76 Results and Discussion

Twenty-two individuals with PCR-confirmed SARS-CoV-2 infection after vaccination were enrolled 77 between January and August 2021 (Table 1). All 8 infections (36%) after 29th June 2021 were 78 79 confirmed by sequencing as delta variant infections. The 14 participants enrolled prior to that date 80 had a diversity of variants including alpha (n=2), gamma (n=1), and mu (n=1). Eight specimens could not be sequenced due to insufficient viral material. Participants with delta and non-delta 81 infections were similar in terms of age, sex, and COVID-19 vaccine manufacturer. Those with delta 82 variant infections had a longer duration of time since completion of vaccination (median 160 vs 29 83 84 days), were somewhat more likely to be symptomatic during their course of infection (100 vs 64%)

and had a higher viral load at the first study specimen collection (5.5 vs 2.0 \log_{10} copies/mL, *P*=0.005).

87

88 Delta variant post-vaccine breakthrough infections were more likely to grow in culture than those with alternate variants (6/8 [75%] vs 3/14 [23%], P=0.03). This pattern was consistent when 89 90 restricted to symptomatic infections only (6/8 [75%] vs 3/9 [33%], P=0.03). Individuals with delta variant infections had slower viral load decay assessed by PCR (median time 13.5 vs 4.5 days, HR 91 92 0.45, 95%CI 0.17, 1.17, Figures 1 & 2A). Although delta variant infection was also associated with 93 lower hazard of conversion to negative viral culture (HR 0.38, 95%CI 0.14, 1.02), the difference in 94 median time to negative viral culture was less pronounced than it was for conversion to negative 95 PCR (median time to negative viral load 7 vs 4 days, Figure 2B). Seven of 8 (88%) individuals with 96 delta variant post-vaccine breakthrough infections had a confirmed negative viral culture within 10 97 days of symptom onset. The remaining participant had culturable virus at day 11 but a negative 98 culture at day 13. That participant remained symptomatic at day 11. 99

100 Similarly, we found evidence that time to negative viral load by PCR was longer for individuals 101 infected more than 3 months after completion of vaccination compared to those infected within 3 102 months of vaccination (median time 13.5 vs 3 days, HR 0.23, 95%CI 0.08, 0.65, Figure 2C), with 103 significant, albeit diminished, difference in time to negative viral culture (median time 7 vs 3 days, 104 HR 0.37, 95%CI 0.15, 0.92, Figure 2D). When considering time from vaccination as a continuous 105 measure, each additional 30 days since completion of vaccination was associated with an additional 106 1.3 days of PCR positivity (95%CI -0.2, 2.6 days) and an additional 0.6 days of viral culture 107 positivity (95%CI -0.8, 13 days, Figure 3). Secondary analyses restricted to symptomatic individuals

- 108 generally showed similar patterns with wider confidence intervals due to the restricted sample size109 (Supplemental Table and Supplemental Figures 1A-D).
- 110
- 111 In this cohort of ambulatory individuals with post-vaccination breakthrough infections,
- symptomatic delta variant SARS-CoV-2 infections were characterized by high initial viral load and a
- 113 longer duration of virologic shedding as detected by PCR (median 13.5 days vs 4.5 days).
- 114 Moreover, identification of replication-competent virus by culture was more common with delta
- variant infections than non-delta infections (75% vs 21%) and the duration of replication-competent
- 116 virus was modestly prolonged among those with delta variant breakthrough infections (7 days vs 3
- 117 days). Nonetheless, we detected only a single breakthrough infection characterized by more than 10
- 118 days of replication-competent virus (11 days) in a participant who remained symptomatic on their
- 119 final day of culture positivity (day 11).
- 120

Unlike our study, a prior study showed similar trajectories and duration of virologic shedding as detected by PCR between delta and alpha viral variants, and shorter duration of shedding among delta variant infections than we found (median 6 vs 13.5 days) (11). We suspect that this difference is explained by distinct features of our study populations. Whereas that former study included relatively young individuals being tested as part of their affiliation with a sports league, study subjects with breakthrough delta infections in our study population were comparatively older adults and accessing SARS-CoV-2 testing through a healthcare system.

128

Our data are in keeping with current guidelines recommending isolation for 10 days or until
symptom resolution for symptomatic post-vaccination breakthrough infections and add new
evidence in support of these guidelines in the delta variant era. These results also reinforce that

post-vaccination breakthrough delta infections should be considered contagious and highlight the
critical importance of prompt testing for symptomatic vaccinated individuals due to the high
frequency of identification of replication-competent virus (5, 12).

135

136 Our study was limited to a small sample (n=22), to those vaccinated, and to non-severe infections in 137 ambulatory individuals. We did not perform ongoing contact tracing in our study. Therefore, our 138 conclusions about contagiousness are limited to inferences about the presence or absence of 139 replication-competent virus, but not confirmation of downstream infections from the cases detected 140 in our study. All delta variant infections in our cohort were mild, but symptomatic, and thus our 141 results should not be generalized to asymptomatic infections. Because of collinearity between delta 142 variant infections and duration of time between vaccination and infection in our cohort, we cannot 143 meaningfully distinguish the relative contributions of these two factors on transmission dynamics in 144 breakthrough infections. Importantly, additional data are also needed to better elucidate the 145 dynamics of delta variant infection in unvaccinated individuals. Work prior to the emergence of the 146 delta variant suggests that the magnitude of viral load and duration of viral shedding is more 147 prolonged among unvaccinated individuals (11, 13). That data in combination with ours, which 148 demonstrates longer shedding of nucleic acid and isolation of replication-competent virus in 149 symptomatic delta variant-infected individuals, suggests that current isolation guidelines might not 150 be adequate for all unvaccinated individuals with delta variant infections. Additional work is also 151 needed to assess transmission dynamics in individuals with severe infection and after vaccine booster 152 administration.

153

154 Methods

155 Study Participants

156 We enrolled non-hospitalized individuals with confirmed SARS-CoV-2 infection after vaccination. 157 Participants were recruited after positive tests through one of two means. First, between January 158 and March of 2021, employees in the Mass General Brigham Medical System were offered weekly 159 COVID-19 testing irrespective of symptoms (14). Following the conclusion of that program, we 160 began recruiting all individuals with positive SARS-CoV-2 PCR test results in the Mass General 161 Brigham Medical System, which includes testing for symptomatic individuals as well as 162 asymptomatic testing for contact tracing and screening procedures (e.g. pre-operative clearance). 163 All adults over 18 who tested positive by either of these systems were eligible for inclusion in this 164 study. For those who consented to participation, we conducted home visits three times weekly until 165 negative PCR testing. At each visit, we obtained self-collected nasal swabs for SARS-CoV-2 PCR, 166 culture and whole genome sequencing. Symptoms were assessed at each specimen collection and 167 through medical chart review after study completion. Symptomatic infections were defined as those 168 with COVID-19-related symptoms at any point during the observation period.

169

170 Viral Load Quantification

171 Viral load quantification and sequencing was conducted as previously reported (14). Briefly, we 172 pelleted virions from nasal swab fluids after centrifugation at 21,000 x g for 2 hours at 4°C. We 173 added TRIzol-LS[™] Reagent (ThermoFisher) to the pellets and incubated the pellets on ice after 174 removing the supernatant. We then vortexed the pellets in 200 µL of chloroform (MilliporeSigma), 175 centrifuged the mixtures at 21,000 x g for 15 minutes at 4°C, removed the aqueous layer, and then 176 treated the resulting solution with an equal volume of isopropanol (Sigma). We then added 177 GlycoBlue[™] Coprecipitant (ThermoFisher) and 100 µL 3M Sodium Acetate (Life Technologies) 178 and incubated the mixtures in dry ice. We produced RNA pellets by centrifugation at 21,000 x g 179 for 45 minutes at 4°C, discarded the supernatant, washed the RNA with cold 70% ethanol, and

180	resuspended it in DEPC-treated water (ThermoFisher). We quantified SARS-CoV-2 RNA virus
181	using RT-qPCR with the US CDC 2019-nCoV_N1 primer and probe set (IDT) (15). Reactions
182	included extracted RNA, 1X TaqPath [™] 1-Step RT-qPCR Master Mix, CG (ThermoFisher),
183	forward and reverse primers, and the probe. We quantified viral copy numbers using N1 qPCR
184	standards in 16-fold dilutions to generate standard curves. Each sample was run in triplicate with
185	two non-template control (NTC) wells that were included as negative controls. Additionally, we
186	tested positive and negative controls alongside all samples. We assessed sample quality by
187	quantifying the Importin-8 (IPO8) housekeeping gene RNA level. Finally, to determine the
188	efficiency of RNA extraction and qPCR amplification, we spiked (RCAS)(16) into each sample as
189	an internal virion control.
190	
191	SARS-CoV-2 Whole Genome Sequencing
192	We performed whole genome sequencing using the Illumina COVIDSeq Test protocol. We
193	constructed libraries using the Illumina Nextera XT Library Prep Kit, then pooled and quantified the

194 libraries using a Qubit High Sensitivity dsDNA kit. Then, we performed genomic sequencing on an 195 Illumina NextSeq 2000, Illumina NextSeq 550, or Illumina NovaSeq SP instrument. Sequences with 196 an assembly length greater than 24000 base pairs were considered complete genomes, and we 197 assigned those sequences a Pango lineage using the most up-to-date version of pangoLEARN 198 assignment algorithm.

199

200 SARS-CoV-2 Spike gene amplification

We additionally performed spike gene amplification, as previously described (14), to determine
variant types for specimens with low viral load to determine variants when whole genome sequencing
was unsuccessful. We used Superscript IV reverse transcriptase (Invitrogen, Waltham, MA, USA) to

204 conduct cDNA synthesis. To exclude PCR artifacts, we used two strategies to amplify the SARS-205 CoV-2 spike gene: 1) Nested PCR amplification with *in-house* designed primer sets that targeted 206 codon 1-814 of the spike gene and 2) the multiplexed primer pools designed with Primal Scheme 207 generating 400-bp tiling amplicons based on the Arctic protocol (17). We separately pooled PCR 208 products from both strategies and performed Illumina library construction using the Nextera XT 209 Library Prep Kit (Illumina, San Diego, CA, USA). We analyzed raw sequence data with PASeq v1.4 210 (https://www.paseq.org). We conducted data filtering with Trimmomatic (v0.30) (18), using min 211 a Q25/5 bp sliding window and a 70 bp minimum length. We filtered out non-viral contamination 212 with BBsplit v35.76 (19). We then merged filtered reads using paired-end read merger v0.9.6 aligned 213 to reference sequences with Bowtie2 v2.1.0) (20). Finally, amino acid variants were identified at the 214 codon level with perl code and used to determine SARS-CoV-2 variant type.

215

216 SARS-CoV-2 culture

217 We performed viral culture as previously reported in the BSL3 laboratory of the Ragon Institute of 218 MGH, MIT, and Harvard (14, 21). Briefly, we detached Vero-E6 cells (ATCC) maintained in 219 DMEM (Corning) supplemented with HEPES (Corning), 1X Penicillin/Streptomycin (Corning), 220 1X Glutamine (Glutamax, ThermoFisher Scientific), and 10% Fetal Bovine serum (FBS) (Sigma) 221 using Trypsin-EDTA (Fisher Scientific) and seeded the cells at 75,000 cells per wells in 24w plates 222 or 20,000 in 96w plates 16-20 hours before infection. We thawed specimens on ice, filtered the 223 specimens through a Spin-X 0.45um filter (Corning) at 10,000 x g for 5min, and diluted them 224 1:10 in DMEM supplemented with HEPES, 1X Penicillin/Streptomycin and 1X Glutamine. We 225 used 100uL of the solution to inoculate triplicate wells in a 24 well plate. We then added 1mL of 226 DMEM supplemented with HEPES, 1X Penicillin/Streptomycin and 1X Glutamine and 2% FBS to 227 each well after 1h of incubation and removal of the viral inoculum. We added 25ul of the undiluted

228	filtrate to four wells of a 96w plate and serial diluted (1:5) the filtrate in media containing 5ug/mL
229	of polybrene (Santa Cruz Biotechnology). We centrifuged the 96w plates for 1 hour at 2000 x g at
230	37C. As a positive control, we used the SARS-CoV-2 isolate USA-WA1/2020 strain (BEI
231	Resources). We observed viral culture plates at 3- and 7-days post-infection with a light microscope
232	and documented wells showing CPE. Lastly, we harvested the supernatant of wells displaying CPE
233	10-14 days post-infection and isolated RNA using a QIAamp Viral RNA Mini kit (QIAGEN) for
234	confirmation of the viral sequence.
235	
236	Statistical Methods
237	We first evaluated patient-specific trajectories of quantitative viral load by PCR over time since

237 index positive test by constructing spaghetti plots. To estimate grouped mean trajectories, stratified 238 239 by variant, we fitted a linear regression model with quadratic and cubic spline terms. We then used 240 the Kaplan-Meier estimator to estimate the survivor function for: (1) time to negative viral by PCR. 241 testing and (2) time to negative viral culture. For both outcomes, we took the time of symptom 242 onset (for symptomatic cases) or time of first positive PCR (for asymptomatic cases) as the origin of 243 the timescale. We selected these definitions of left censoring to replicate US CDC isolation 244 guidelines. For both outcomes, we estimated survivor functions stratified by delta versus non-delta 245 variant infection and, separately, by duration of time from vaccination to infection, dichotomized as 246 greater versus less than 90 days. We next fitted cox proportional hazards model with both outcomes 247 and delta versus non-delta variant infection and, separately, time since completion of vaccination as 248 predictors. In sensitivity analyses to assess for potential confounding by the presence of absence of 249 symptoms, we re-estimated Kaplan-Meier survivor functions after limiting the sample to individuals 250 with symptomatic infection. Finally, we fit linear regression models and plotted scatter plots to

- assess relationships between duration of PCR and culture positivity and time since completion of
- 252 vaccination as a continuous measure.
- 253
- 254 Study Approval
- 255 Study procedures were reviewed and approved by the Human Subjects Institutional Review Board
- and the Institutional Biosafety Committee at Mass General Brigham. All participants gave verbal
- informed consent, as written consent was waived by the review committee based on the risk to
- benefit ratio of requiring in-person interactions for an observational study of COVID-19.
- 259
- 260

261

262 Author contributions

- 263
- MJS conceived of the study design, participated in the data analysis, drafted the initial manuscriptand contributed editorial input.
- 266 JB conducted experiments, participated in the data analysis, and contributed editorial input.
- 267 RG directed the data collection, participated in the data analysis, and contributed editorial input.
- 268 RU participated in data collection, data analysis, and contributed editorial input
- 269 JL participated in the data analysis and contributed editorial input.
- 270 SH participated in the data analysis and contributed editorial input.
- 271 TV participated in the data collection and contributed editorial input.
- 272 ZR participated in the data collection and contributed editorial input.
- 273 SI participated in data collection and contributed editorial input.
- 274 GC participated in data collection and contributed editorial input.
- 275 RG participated in data collection and contributed editorial input.
- 276 CMN participated in data collection and contributed editorial input.
- 277 CAS participated in data collection and contributed editorial input.
- 278 JR participated in the data collection, conducted experiments and contributed editorial input.
- 279 JF conducted experiments and contributed editorial input.
- 280 MC conducted experiments, participated in the data analysis and contributed editorial input.
- JV conceived of the study design, provided reagents and contributed editorial input.
- AB conceived of the study design, provided reagents, participated in the data analysis, andcontributed editorial input.
- 284 JL conceived of the study design, provided reagents, participated in the data analysis, and
- contributed editorial input.
- JZL conceived of the study design, provided reagents, participated in the data analysis, andcontributed editorial input.
- 287 contributed editorial input. 288
- All authors approve of the final version of the manuscript.
- 290
- 291

292 Acknowledgments

- 293 The study team would like to thank Dr. Marcia Goldberg for her contributions to this work.
- 294

295 References

- 296 1. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral
- 297 Diseases. *Quarantine and Isolation [Internet]*. Centers for Disease Control and Prevention; 2021:
- 298 2. Wölfel R et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*2020;581(7809):465–469.
- 300 3. Owusu D et al. Persistent SARS-CoV-2 RNA Shedding without Evidence of Infectiousness: A
- 301 Cohort Study of Individuals with COVID-19. *J Infect Dis* 2021;jiab107.
- **302** 4. Bullard J et al. Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From
- **303** Diagnostic Samples. *Clin Infect Dis* 2020;71(10):2663–2666.
- **304** 5. Arons MM et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing
- **305** Facility. *N Engl J Med* 2020;382(22):2081–2090.
- **306** 6. GISAID Initiative. *Tracking of Variants [Internet]*
- 307 7. Liu Y, Rocklöv J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher
- 308 compared to the ancestral SARS-CoV-2 virus. *J Travel Med* 2021;taab124.
- 309 8. Li B et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-
- **310** *CoV-2 Delta variant [Internet].* Epidemiology; 2021:
- 9. Mlcochova P et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
- 312 [Internet]. *Nature* [published online ahead of print: September 6, 2021]; doi:10.1038/s41586313 021-03944-y
- 314 10. Wang Y et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-
- CoV-2 Delta VOC in Guangzhou, China. *EClinicalMedicine* 2021;40:101129.
- 316 11. Kissler SM et al. Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated
- 317 *individuals [Internet]*. Epidemiology; 2021:
- 318 12. Kim M-C et al. Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19.
- 319 *N Engl J Med* 2021;384(7):671–673.
- 320 13. Levine-Tiefenbrun M et al. Initial report of decreased SARS-CoV-2 viral load after inoculation
- 321 with the BNT162b2 vaccine. *Nat Med* 2021;27(5):790–792.
- 322 14. North CM et al. Determining the Incidence of Asymptomatic SARS-CoV-2 among Early
- 323 Recipients of COVID-19 Vaccines: A Prospective Cohort Study of Healthcare Workers before,
- during and after Vaccination [DISCOVER-COVID-19]. *Clin Infect Dis* 2021;ciab643.
- 325 15. Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primers and
- **326** Probes. Centers for Disease Control and Prevention.
- 327 [Internet]https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html.
- **328** cited April 1, 2021
- 329 16. Palmer S et al. New real-time reverse transcriptase-initiated PCR assay with single-copy
- sensitivity for human immunodeficiency virus type 1 RNA in plasma. *J Clin Microbiol*
- **331** 2003;41(10):4531–4536.
- 332 17. Quick J. nCoV-2019 sequencing protocol v3 (LoCost) V.3
- 333 [Internet]https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye.
- 334 cited
- 18. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 2014;30(15):2114–2120.
- **337** 19. Bushnell B. *BBMap: A Fast, Accurate, Splice-Aware Aligner [Internet]*. Lawrence Berkeley
- 338 National Lab. (LBNL), Berkeley, CA (United States); 2014:
- 339 20. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nature Methods
- **340** 2012;9(4):357–359.
- 341 21. Yonker LM et al. *Virologic features of SARS-CoV-2 infection in children [Internet]*. Infectious
- 342 Diseases (except HIV/AIDS); 2021:

344 345

Table 1. Cohort characteristics

	Delta Variant Infections (n=8)	Non/Pre-Delta Variant Infections (n=14)#	<i>P</i> - value [†]
Age (mean, SD)	47 (16)	41 (16)	0.41
Female Sex (n %)	4 (50%)	8 (57%)	>0.99
Days since full Vaccination* (median, IQR)	160 (152- 185)	29 (7-54)	0.002
Vaccine received (n, %)			0.27
Moderna	3 (38%)	9 (64%)	
Pfizer/BioNTech	4 (50%)	5 (36%)	
Johnson & Johnson/Janssen	1 (13%)	0 (0%)	
Isolation of replication-competent virus (n, %)	6 (75%)	3/14 (21%)	0.020
Symptomatic infection (n, %)	8 (100%)	9 (64%)	0.115
Culturable virus among those with symptomatic infection $(n, \%)$	6 (75%)	3/9 (33%)	0.153
First study viral load (log10 copies/mL, median, IQR)	5.6 (4.7 - 6.2)	ND (ND - 5.1)	0.02]

346

347 SD: standard deviation; IQR: Interquartile range; ND: Not detected

[#]Eight participants with specimens with insufficient virus for sequencing but collected prior to 18th

June 2021 (when delta first made up more than 10% of sequenced virus in Massachusetts) arepresumed pre-delta

251 *T 11

351 *Two non-delta variant infections had received one dose at the time of infection and were

352 considered to have 0 days from full vaccination

^{*}P-values represent statistical tests comparing delta and non-delta variant breakthrough infection

354 characteristics and were estimated using rank sum non-parametric tests for continuous variables

355 (age, days since vaccination, first study viral load) and exact Fischer tests for categorical variables


356 (sex, vaccine received, symptomatic infection, and culturable virus).

357

358


359


Figure 1. Viral load decay curve in individuals with post-vaccination breakthrough SARS-CoV-2 infection with non-delta (A) and delta variant infections




Trajectory of viral load by PCR from time of index positive test for each study participant with non-delta variant (A) and delta variant (B) PCR-confirmed SARS-CoV-2 infection. Each connected solid line represents a participant. The solid dashed lines represent the total population mean line of fit derived from a regression equation including quadratic and cubic terms. The dotted line represents a similar line of fit, but restricted to individuals who remained positive at day 3. Timepoints denoted with asterisks were viral culture positive.

Figure 2. Kaplan-Meier curves indicating days to negative viral load (A) and negative culture (B) by viral variant and days to negative viral load (C) and negative culture (D) by duration of time since completion of COVID-19 vaccination. Observation time begins at the date of positive PCR for asymptomatic cases and date of symptom onset for symptomatic cases.







Each point on the graph indicates an individual with post-vaccination breakthrough COVID-19 infection. Vaccines received are indicated by plot labels as Moderna (M), Pfizer/BioNTech (P), or Johnson & Johnson/Janssen (J). Black solid lines indicated the line of best fit from linear regression models, whereas gray shaded area indicates the 95% confidence interval around this estimate. R-squared and *P*-values are estimates from these models. Green triangles indicate delta variant infections whereas blue diamonds represent non-delta variant infections.